CareDx (CDNA) Projected to Release Quarterly Earnings on Thursday

CareDx (NASDAQ:CDNA) is expected to be issuing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $0.22 per share and revenue of $113.83 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.23. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The company had revenue of $117.70 million during the quarter, compared to the consensus estimate of $102.03 million. During the same quarter in the previous year, the firm posted $0.09 earnings per share. CareDx’s revenue for the quarter was up 39.3% compared to the same quarter last year. On average, analysts expect CareDx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Trading Down 1.5%

Shares of CDNA stock traded down $0.55 during trading hours on Tuesday, reaching $35.81. 167,314 shares of the company’s stock were exchanged, compared to its average volume of 790,972. CareDx has a 1 year low of $11.26 and a 1 year high of $40.47. The stock has a market cap of $1.85 billion, a PE ratio of -223.62 and a beta of 2.43. The stock’s fifty day moving average price is $27.23 and its two-hundred day moving average price is $22.07.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Weiss Ratings cut shares of CareDx from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, July 15th. BTIG Research raised their price target on CareDx from $28.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Wall Street Zen raised CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. William Blair raised CareDx to a “hold” rating in a report on Thursday, July 16th. Finally, Craig Hallum reaffirmed a “hold” rating and set a $35.00 price target on shares of CareDx in a research note on Thursday, July 16th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, CareDx presently has a consensus rating of “Hold” and a consensus price target of $33.67.

Insiders Place Their Bets

In related news, Director Hannah Valantine sold 12,103 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the sale, the director owned 36,686 shares of the company’s stock, valued at approximately $847,813.46. This trade represents a 24.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the completion of the sale, the chief executive officer directly owned 661,959 shares in the company, valued at approximately $19,355,681.16. This represents a 5.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 78,936 shares of company stock valued at $2,093,708. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. State Street Corp grew its holdings in shares of CareDx by 6.7% during the fourth quarter. State Street Corp now owns 2,737,752 shares of the company’s stock valued at $51,579,000 after buying an additional 171,303 shares during the last quarter. Bamco Inc. NY raised its position in shares of CareDx by 11.2% during the 2nd quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock valued at $47,593,000 after buying an additional 245,651 shares in the last quarter. Deerfield Management Company L.P. purchased a new position in shares of CareDx during the third quarter worth approximately $31,857,000. Dimensional Fund Advisors LP boosted its holdings in CareDx by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,309,980 shares of the company’s stock valued at $24,681,000 after acquiring an additional 93,456 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of CareDx by 18.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after purchasing an additional 170,504 shares during the last quarter.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.